Install
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
IXJ vs XPH: Global Healthcare ETF or Pharma Focus?
1+ day, 21+ hour ago (475+ words) The iShares Global Healthcare ETF (NYSEMKT:IXJ) offers broad sector diversification and lower volatility, while the State Street SPDR S&P Pharmaceuticals ETF (NYSEMKT:XPH) provides concentrated exposure to U.S. drugmakers. Investors seeking healthcare exposure must choose between broad-sector and sub-industry…...
Amgen vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026?
2+ day, 8+ hour ago (463+ words) Investors choosing between Amgen (NASDAQ:AMGN) and Revolution Medicines (NASDAQ:RVMD) must weigh established cash flows against high-stakes clinical potential. Which of these healthcare players is the better addition to your portfolio today? Amgen is a titan of the biotech…...
Which Is the Better Healthcare ETF: Fidelity's Low-Cost FHLC or First Trust's High-Conviction FBT?
3+ day, 1+ hour ago (612+ words) Fidelity MSCI Health Care Index ETF provides broad sector exposure with 365 holdings at a much lower cost than First Trust NYSE Arca Biotechnology Index Fund. First Trust NYSE Arca Biotechnology Index Fund focuses on a concentrated basket of 30 biotechnology stocks,…...
Is This the Right Time to Add Neogen Stock to Your Portfolio?
2+ day, 23+ hour ago (470+ words) Over the past year, this Zacks Rank #2 (Buy) stock has surged 107.7% against the 29.3% fall of the industry and the S&P 500’s 17.5% rise. The renowned food and animal safety product provider has a market capitalization of $2.59 billion. Neogen surpassed earnings…...
AMGN: Strong revenue growth, pipeline advances, and disciplined investment drive long-term outlook
2+ day, 21+ hour ago (70+ words) tradingview.com AMGN: Strong revenue growth, pipeline advances, and disciplined investment drive long-term outlook Quarterly revenues exceeded $10 billion, driven by strong growth across six key product areas and robust pipeline progress. Landmark clinical results for IMDELLTRA and TEZSPIRE, expanding biosimilar…...
Amgen Stock Sank 9.6% After Novartis’s Trial Failure and a Tavneos Suspension
4+ day, 6+ hour ago (300+ words) Test your own Repatha growth assumptions with TIKR’s free Valuation Model (It’s free) >>> If Amgen can successfully appeal the Tavneos decisions using its real-world evidence, the stock’s sharp pullback this week may prove overdone relative to the underlying business. See…...
Amgen's Forward Multiple Looks Cheap Until You Price The Margins It Assumes
4+ day, 6+ hour ago (147+ words) Trefis This site requires JavaScript to function properly. Here are some sample widgets you could interact with from this dashboard: NYSE/AMEX data delayed 20 minutes. NASDAQ and other data delayed 15 minutes unless indicated. This interactive model has a limit on…...
Amgen caught in the crossfire of Novartis' failure
4+ day, 22+ hour ago (241+ words) marketscreener.com On Friday evening, Novartis announced that the Phase III study, focused on cardiovascular events, did not meet its primary endpoint, which was a reduction in the risk of cardiovascular events with its product Pelacarsen versus placebo The Swiss…...
Amgen announces Phase 3 DLL3-therapy study met primary endpoint as stock falls 7.5%
4+ day, 18+ hour ago (260+ words) Traders Union Amgen announces Phase 3 DLL3-therapy study met primary endpoint as stock falls 7.5% Amgen announced on August 21, 2026, that a Phase 3 trial evaluating its DLL3-targeting therapy as part of first-line maintenance for extensive-stage small cell lung cancer met its primary endpoint....
Amgen Shares Fall as Novartis' Pelacarsen Misses Phase III Study Goal
5+ day, 22+ hour ago (347+ words) Shares of Amgen AMGN were down 5% in after-hours trading on Friday after Novartis NVS announced that the phase III Lp(a)HORIZON study evaluating the latter's investigational drug pelacarsen in patients with elevated lipoprotein (a) Lp(a) and established cardiovascular disease (CVD) did not…...